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HIV-1 Consistently Evades the
Humoral Immune Response
More than 25 years have passed since
the discovery of HIV type 1, the causative
agent of AIDS, and the first vaccine
candidate to exhibit evidence for protec-
tion against infection was reported only
recently [1]. However, the extent and
mode of protection are still under debate
[2]. Thus, a vaccine that effectively
stimulates complete protective immunity
by the cellular branch (cytotoxic T lym-
phocytes) and/or the humoral branch
(antibodies) of the immune system has
yet to emerge. Among the millions of
people who have received treatment for
the disease and the many more who have
tested HIV positive, there exists no
definitive case in which a potent neutral-
izing antibody response enabled an infect-
ed individual to successfully clear or
control the infection. In a small percentage
of cases, individuals will exhibit a natural
ability to suppress viral replication and
progression of the disease. However, the
explanation for the existence of this rare
phenotype has primarily converged on a
robust cellular immune response, with
evidence generally lacking for a significant
contribution to viral control by antibodies
[3–5].
Structural features of the HIV envelope
spike are critical to its unusual ability to
escape neutralizing antibodies. However,
many of the identified features are not
unique to this virus. Here, we propose
another strategy HIV employs to evade
antibodies: the low density of envelope
spikes, a distinguishing feature when
compared with viruses to which protective
neutralizing antibody responses are con-
sistently raised, directly impedes bivalent
binding by immunoglobulin G (IgG)
antibodies. The result is a minimization
of avidity, normally used by antibodies to
achieve high affinity binding and potent
neutralization, thereby expanding the
range of mutations that allow HIV to
evade antibodies. Understanding limita-
tions to avidity may be essential to the
design of anti-HIV vaccines and therapies.
The HIV Spike Structure and Its
Rapid Mutation Facilitate
Antibody Evasion
Tremendous effort has been devoted to
understanding why HIV so effectively
evades antibodies. Accepted explanations
include rapid mutation of the two glyco-
proteins that comprise the envelope spike,
gp120 and gp41, and structural features
that enable the spike to hide conserved
epitopes from antibodies. These structural
features include a shield of host-derived
carbohydrates [6], conformational mask-
ing [7], steric occlusion [8], the protection
of conserved regions at interfaces by
oligomerization or in narrow pockets [9–
11], and the presence of highly variable
flexible loops that shield conserved epi-
topes on the envelope spike [9,12]. In
addition, it was recently hypothesized that
a lack of germline genes capable of
maturing into potent anti-HIV antibodies
may represent holes in the potential
antibody repertoire [13].
While the importance of the envelope
spike’s structural attributes to limiting
antibody potency are well established,
they are not unique to HIV. For example,
the receptor binding sites of both rhinovi-
rus and influenza are narrow pockets
predicted to be inaccessible to antibodies
[14], and mutation, loop decoys, and
glycan shielding have all been implicated
in antibody evasion by influenza [15,16].
Nevertheless, these viruses and many
others and/or the vaccines that have been
developed against them elicit potent neu-
tralizing antibody responses that signifi-
cantly contribute to their clearance or
provide sterilizing immunity [17].
What distinguishes HIV from other
viruses in relation to antibody-mediated
neutralization? Is it simply that HIV is
more adept at employing the evasion
strategies outlined above? While it is clear
that HIV is superbly adapted for evading
antibodies based on these strategies (as
described in recent reviews [15,18]), we
propose an additional contributing factor
in its ability to escape neutralization by
antibodies [19], which is based on recent
data that describe the spatial arrangement
of spikes on its surface. The reasoning is
rooted in an inherent limitation to the
architecture of an antibody as it relates to
avidity, which in this context refers to the
ability of a bivalent antibody to simulta-
neously bind two epitopes tethered to the
same surface [20]. We begin with com-
parisons of available neutralization data
and the spatial arrangements of envelope
spikes for HIV and other viruses, then
present a discussion of avidity and the
factors that influence it, and end with
speculations on how a greater understand-
ing of the factors that aid or inhibit avidity
might be used to further inform vaccine
design.
Comparison of Monovalent and
Bivalent Binding of Antibodies
to Viruses
Most of the neutralizing activity in the
sera of HIV-positive individuals can be
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attributed to antibodies of the IgG subclass
[21,22], which represent the predominant
class of immunoglobulin in blood. IgG
antibodies are composed of an Fc region
fused to two identical Fabs (Figure 1).
Antigens bind to the tip of each Fab,
which present the unique surfaces that
define the epitope specificity of the anti-
body. While the immune system can draw
from an almost unlimited sequence library
to change the specificity of the Fabs, the
antibody architecture is relatively con-
stant, including the range of permissible
end-to-end distances between the Fabs.
The Fabs are linked to the Fc region by a
flexible hinge, which typically allows a 10–
15-nm center-to-center separation be-
tween the antigen-binding sites of the
two Fabs for IgGs.
In the context of antibodies, the term
avidity refers to their ability to bind two
physically linked antigens simultaneously
(e.g., to the surface of the same virus). The
result of avidity can be a dramatic increase
in the strength of the binding as compared
to a monovalent 1:1 interaction such that
once bound, the antibody interaction with
antigen becomes essentially irreversible
over biologically relevant time scales
[23]. Antibodies have been shown to bind
bivalently to non enveloped viruses such as
rhinovirus and poliovirus, which contain a
rigid icosahedrally symmetric outer pro-
tein shell with closely spaced epitopes.
Thus, rhinovirus and poliovirus saturate
with 30 IgGs bound via both Fabs to 60
repeating epitopes created by 30 2-fold
symmetry axes [24,25]. An early demon-
stration of the importance of avidity in
IgG binding to poliovirus revealed that
using papain to digest the antibody and
create monovalent Fabs led to a substan-
tial increase in the molar concentration
required to inhibit infection in vitro [25].
By contrast, a limited role for avidity in
neutralization of HIV by some antibodies
is suggested by the relatively modest
increases in neutralization potencies of
IgGs as compared to their corresponding
Fabs [26–28]. In addition, conversion of
the broadly neutralizing anti-HIV anti-
bodies 2F5 and 4E10 from IgGs with two
combining sites to dimeric IgA (four Fabs)
and/or pentameric IgM (ten Fabs) either
did not improve their neutralization effi-
ciencies or abrogated activity altogether
[29,30]. Similarly, we have observed
equivalent neutralization potencies for
the anti-HIV antibody b12 when tested
as an IgA, IgM, or IgG (P. Gnanapra-
gasm, R. Galimidi, J. Klein, A. West, Jr.,
and P. Bjorkman, unpublished data).
One way to quantitatively assess the
effects of antibody avidity is to compare
the neutralization potency values of a Fab
and its parental IgG. We define the molar
neutralization ratio (MNR) as the concen-
tration in an in vitro neutralization assay
at which a Fab achieves 50% inhibition of
viral infectivity (IC50) divided by the IC50
for the parental IgG. If an antibody binds
only monovalently to the viral surface (i.e.,
it is incapable of cross-linking epitopes on
the virus), it would inhibit at an approx-
imately 2-fold lower concentration than
the Fab (MNR=2) because the IgG has
twice the number of antigen-binding sites
[31]. MNRs greater than 2 suggest avidity
effects resulting from the IgG cross-linking
epitopes on the virus. Results from pub-
lished studies show high MNRs for
respiratory syncytial virus (RSV) [32] and
influenza [31,33] (Figure 2), suggesting
that antibodies can take advantage of
avidity effects to bind to enveloped viruses.
However, a compilation of the highest
reported MNRs we could find for anti-
bodies against HIV [26–28] shows that
neutralizing antibodies, including those
that serve as models for the types of
antibodies that researchers would most
like to elicit with an HIV vaccine, yield
relatively low MNRs (Figure 2). This
suggests a general limitation to bivalent
binding of IgGs to HIV. We propose that
the spatial distribution of envelope spikes
on HIV, combined with the distribution of
protein epitopes on the spike trimer,
explains the predominantly monovalent
binding of anti-HIV antibodies, which in
turn limits the ability of the humoral
immune response to prevent viral escape
by mutation.
HIV Envelope Spikes Are
Present at Low Density
Enveloped viruses such as HIV contain
an outer shell composed of a cell-derived
lipid membrane displaying embedded
antigens that were acquired during bud-
ding from the host cell. Consequently,
enveloped viruses generally lack the struc-
tural elements of non-enveloped viruses
that enforce a symmetric arrangement of
antigens in non-enveloped viruses. Elec-
tron micrographs of enveloped viruses for
which antibody-mediated neutralization is
known to be critical to the control and/or
elimination of infection [17,34] generally
reveal a high density of envelope spikes.
For example, influenza type A virus
incorporates ,450 spikes per virus particle
spaced at intervals #10 nm [35]
(Figure 3A). Similarly, measles, RSV, and
hepatitis B virions include large numbers
of closely spaced spikes (Figure 3B–3D).
Indeed, the high densities of repetitive,
Figure 1. Scale model of an IgG anti-
body. Red denotes the locations of antigen
recognition sites. A longer than typical sepa-
ration distance (17 nm) was reported for the
structure of intact b12 IgG [69]. The longer
distance resulted in part from an unusually
long CDR3 loop protruding from the antigen-
combining site of each Fab. As this loop wraps
around the CD4-binding loop on gp120 [64],
the effective separation distance on this IgG
and other antibodies with protruding CDR3
loops would be ,15 nm.
doi:10.1371/journal.ppat.1000908.g001
Figure 2. Bar graph of the highest report-
ed molar neutralization ratios (MNRs).
MNRs were reported for monoclonal antibodies
against HIV [26,27,28], RSV [32], and influenza
[31,33]. The MNR for each antibody was
calculated as the IC50 of the Fab divided by
the IC50 of the IgG derived from in vitro
neutralization assays (IC90s were reported for
some influenza IgG/Fab comparisons [31], but
IC50 ratios would be nearly the same because
the slopes of the inhibition curves were similar).
MNRs for a particular IgG/Fab combination can
vary with the strain of virus being tested
because the degree to which cross-linking can
benefit an IgG depends on the affinity of the
Fab for its antigen. Differences in size between a
Fab and IgGmay also influence the MNR if steric
factors play a role in the neutralization mech-
anism of a particular antibody. However, this
effect is probably minor, as (Fab)92 fragments
generally exhibit similar neutralization potencies
to their parental IgGs [31,33]. Not shown are
high MNR values (,70) derived for IgG/Fab
comparisons involving HIV virions with a gp41
cytoplasmic tail truncation [70]. The tail deletion,
which is rarely observed in vivo, has been
suggested to increase the mobility of envelope
trimers [70] and/or increase the number of
spikes per virion [71], so its effects on intra-spike
cross-linking are not well understood.
doi:10.1371/journal.ppat.1000908.g002
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identical epitopes on the surfaces of non-
enveloped icosahedral viruses and envel-
oped viruses such as vesticular stomatitis,
rabies, influenza, and Sindbis allow induc-
tion of T cell–independent B cell activa-
tion during the elicitation of the humoral
immune response [36]. In striking con-
trast, biochemical studies and cryo-elec-
tron tomography (cryo-ET) reconstruc-
tions showed that HIV, although similar
in size to influenza type A, has an average
of ,14 spikes per virus particle (the full
range from published studies is four to 35
spikes) [37–41] (Figure 3E). Despite the
dearth of envelope spikes, HIV remains
infectious, as it has been shown that as few
as four spikes are sufficient for viral
attachment [42], and possibly fewer may
be needed to achieve fusion with the target
cell membrane [43,44].
Low Spike Density and Spike
Structure Impede Bivalent
Binding by IgGs to HIV
What are the consequences of the low
number of envelope spikes on HIV virions
to antibody binding? Cryo-ET studies of
HIV particles allowed an analysis of
nearest neighbor distances between indi-
vidual spikes, revealing that the low
number of envelope spikes also translates
to a low spike surface density. Thus, the
majority of nearest neighbor distances fall
outside of the range of the two Fabs of an
IgG [38] (Figure 3F) as previously pre-
dicted [45], leaving a minority of HIV
envelope spikes available for cross-linking
by a bivalent antibody. Inter-spike cross-
linking might still be possible if spikes were
able to freely diffuse within the viral
membrane, but analyses of cryo-ET data
[38] and evidence for interactions between
the cytoplasmic tail of gp41 and the matrix
protein of HIV [46,47] suggest that the
arrangement of spikes on a virus particle is
likely to be static over time periods
relevant to neutralization.
Cross-linking within a spike trimer (intra-
spike cross-linking) represents another way
to achieve bivalent binding of an IgG.
However, cryo-ET structures of HIV spike
trimers bound to Fabs [39] and molecular
modeling based on crystal structures [27,48]
suggest that bivalent binding within a single
trimeric spike is also unlikely, at least for
antibodies directed against gp41 or the
CD4-binding site of gp120. Therefore, most
anti-HIV antibodies probably bind only one
epitope per spike. Anti-carbohydrate anti-
bodies may be an interesting exception:
since a single spike subunit contains many
carbohydrate attachment sites, an anti-
carbohydrate antibody can bind using both
Fabs to adjacent carbohydrate sites within a
spike monomer. Although antibodies that
recognize viral carbohydrates are rare
because viral carbohydrates are usually
non-immunogenic, one broadly neutralizing
antibody against HIV, IgG 2G12, presents
its two Fabs as a single domain-swapped
structure that recognizes a constellation of
viral carbohydrates within gp120 [49] and
appears to be unusually effective in confer-
ring protection against infection in vivo [50].
A naturally occurring dimeric form of IgG
2G12 composed of four Fabs and two Fcs
was recently found to exhibit a 100- to 160-
fold average increased molar neutralization
potency over its monomeric form, with an
increase of$500-fold against seven of the 21
strains tested [51], suggesting an enhanced
ability to cross-link carbohydrate epitopes on
a single envelope spike. Another exception
might be represented by a new class of
highly potent and broadly neutralizing anti-
HIV antibodies, which include PG9 and
PG16 [52]. The location of the proposed
epitope for these antibodies, at the top of the
envelope spike, might allow both Fabs of a
single IgG to bind the same spike trimer.
How Avidity Can Enhance
Antibody Potency: A
Theoretical Examination
The affinity of a monomeric Fab, given
by the equilibrium dissociation constant
(KD), is equal to the dissociation rate
constant (koff), divided by the association
rate constant (kon). Overall, avidity mani-
fests as an increase in the observed affinity
of an IgG (a decrease in the KD) when
binding two tethered antigens such that
saturation of a surface can be achieved at
lower concentrations as compared to a
monovalent Fab. The affinity increase is
mostly due to a reduction in the observed
dissociation rate for the IgG such that
binding to antigen becomes virtually
irreversible over time scales relevant to
the lifetime of a pathogen [23]. The effects
of avidity on the affinity of an antibody
can be modeled as a two-step reaction
involving one antibody molecule and two
epitopes tethered to the same surface
(Figure 4A). After becoming tethered to
its target through the first Fab, the small
Figure 3. Comparison of enveloped viruses and nearest neighbor distances for HIV
envelope spikes. (A) Influenza type A virus. Image provided by Drs. Masashi Yamaguchi and
Kuniaki Nagayama. (B) Measles virus. Image reproduced with permission from Dr. Shmuel
Rozenblatt from http://www.tau.ac.il/lifesci/departments/biotech/members/rozenblatt/figures.
html. (C) RSV (image credit: US Centers for Disease Control and Prevention). (D) Hepatitis B
virus. Image provided by Drs. Kelly Dryden and Mark Yeager. (E) HIV type 1. Image provided by
Drs. Ping Zhu and Kenneth Roux. See also [38]. Many schematic pictures of HIV in textbooks and
on Web sites show more spikes per virion. Some of these figures were based on early electron
micrographs of a mutant simian immunodeficiency virus containing a higher number of spikes
per viral particle [72]. Others were based on the incorrect assumption that HIV exhibits
icosahedral symmetry. (F) Distribution of nearest neighbor distances between HIV spikes derived
from cryo-ET analyses of 40 HIV virions. Data were taken from [38]. Although some spike
clustering was reported [38], the virions exhibited a large distribution of nearest neighbor
distances between spikes (7–80 nm center to center).
doi:10.1371/journal.ppat.1000908.g003
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reaction volume of the second forward
reaction serves to increase the second
reaction rate [53], but this second binding
step can only occur if the second binding
site lies within the volume that is accessible
to the free Fab arm. A corollary of the
model for avidity is that the potency of a
neutralizing IgG that can bind bivalently
to two epitopes simultaneously on the
same surface of a pathogen will primarily
depend on the magnitude of kon. In
contrast, the potency of a Fab or an IgG
that binds monovalently will depend on
the magnitudes of both the kon and the koff.
The predicted insensitivity of an IgG to
changes in koff under conditions permissible
to bivalent binding was demonstrated for
palivizumab, a monoclonal antibody direct-
ed against RSV [32], an enveloped virus
with a high spike density (Figure 3C). A
comparison of neutralization potencies of
Fabs and their parental IgGs for a library of
antibody variants derived from palivizumab
demonstrated that mutations that decreased
koff did not change the potency of the
corresponding IgG but did increase the
neutralization potency of the Fab [32]
(Figure 4B). Furthermore, as predicted by
avidity effects, mutations that increased kon
served to increase the neutralization poten-
cies of both the Fab and the IgG [32]. Thus,
for cases in which efficiently cross-linking the
surface of a virus is likely (e.g., RSV or
influenza), an antibody can maintain a
relatively unchanged neutralization potency
even as the virus accumulates mutations that
increase its koff. However, in cases in which
efficient cross-linking is unlikely (e.g., HIV),
the virus can escape antibody-mediated
neutralization with mutations that weaken
either rate constant, resulting in a virus that
canmore easily escape the humoral immune
system during the course of an infection.
How Understanding Limitations
to Avidity Can Inform the
Design of Anti-HIV Vaccines
and Therapies
The vertebrate immune system is re-
markable in its ability to respond to and
clear infections. Unfortunately, the rela-
tively fixed distance between the two
antigen-binding sites of an IgG and a
reliance on avidity as a mechanism to
achieve higher affinities makes it suscepti-
ble to evasion by pathogens that employ
high mutation rates coupled with low
antigen densities. When compared to the
antigen densities present on the surfaces of
viruses to which neutralizing antibody
responses can be consistently raised
(Figure 3A–3D), it seems an unlikely
coincidence that HIV—a virus that is
among the most adept at evading anti-
body-mediated neutralization—also stands
out as having an unusually high mutation
rate and an unusually low density of
surface envelope spikes with apparently
restricted mobility. Thus, it is tempting to
speculate that whereas antibodies evolved
to form a bivalent structure that enhances
binding to pathogen surfaces through
avidity effects, HIV evolved a low spike
density designed to specifically thwart
bivalent binding by antibodies.
In the initial immune response to a
particular variant of HIV, it is likely that
IgGs will exhibit sufficiently slow dissoci-
ation rates and high enough affinities to
exert selective pressure even when binding
monovalently, whether by neutralization
of virus particles or by recruiting effector
functions against infected cells. However,
faced with a target to which bivalent
binding is predominantly impossible, anti-
body potency will be susceptible to escape
by a wider range of mutations: ones that
serve to decrease the rate of association as
well as ones that serve to increase the rate
of dissociation. The immune system may
respond with revisions to the antibody
repertoire, but the rate at which new
antibodies are made will be easily out-
paced by the virus’s rate of mutation.
Without the buffering effect against
escape by mutation that avidity provides,
it is likely that immunogens derived from
HIV will need to be specifically tailored to
focus the antibody response against only
the most conserved epitopes—a key ob-
jective that has already been identified by
many research groups [54,55]. Viewed
through the lens of avidity considerations,
a general deficiency in bivalent binding
will impose the additional requirement
that broadly neutralizing antibodies still
exhibit high affinities for their epitopes
when binding monovalently. An alterna-
tive approach, as others have proposed
[56,57], may lie in eliciting anti-carbohy-
drate antibodies, as the high density of
glycans on each gp120 monomer should
enable efficient bivalent binding to indi-
vidual envelope spikes. Thus, new immu-
nogens designed to elicit antibodies capa-
Figure 4. Bivalent binding model and effect of dissociation rate on neutralization in
bivalent and monovalent binding. (A) Schematic of the step-wise bivalent binding model of
an IgG to two envelope spikes (Ag, antigen) tethered to the same surface (kon, association rate
constant; koff, dissociation rate constant; kon*, enhanced association rate constant resulting from
the small reaction volume of Reaction 2). (B) Comparison of the effect of the Fab dissociation rate
constant (koff) on the neutralization potency of Fab (left) and IgG (right) variants of palivizumab, a
monoclonal antibody against RSV. Adapted from Table 1 in [32]. The names of the Fab/IgG pairs
were changed to A–G for clarity. A, AFFFd; B, AFFYd; C, AFSFd; D, AFFGd; E, W100F; F, S32A; G,
wild type (see [32] for an explanation of mutant nomenclature). Note that these results suggest
that high affinity Fabs with slow dissociation rates (e.g., Fabs selected by techniques such as
phage display) may not exhibit increased neutralization potencies, particularly against a densely
packed virus, when converted to bivalent IgGs.
doi:10.1371/journal.ppat.1000908.g004
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ble of intra-spike cross-linking—either
carbohydrate epitopes within or between
spike monomers, or protein epitopes
between spike monomers—may prove
critical to the induction of a broadly
cross-reactive neutralizing antibody re-
sponse.
Using available crystallographic [9,58–
66] and electron microscopy data [35,37–
39,67,68], it might also be possible to
engineer novel bivalent and multivalent
antibody architectures that are capable of
intra-spike cross-linking by increasing the
reach between Fabs using insertions in the
hinge region of an IgG that adopt
extended conformations [19], although
they would need to be administered via
passive immunization or gene therapy.
Carbohydrate-binding reagents specific
for HIV (perhaps based on the anti-
carbohydrate antibody 2G12) might be a
logical starting point, as multimerization of
2G12 has been shown to significantly
enhance its neutralization potency
[30,51]. These engineering approaches,
as well as the design of immunogens able
to elicit intra-spike cross-linking antibod-
ies, could hold a significant advantage in
that either approach would make the low
spike density on HIV irrelevant to neu-
tralization potency.
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